Medical Disclaimer: This content is for educational and informational purposes only. It does not constitute medical or financial advice. Drug pricing changes frequently. Always consult a licensed healthcare provider before starting any weight loss treatment. Savings program eligibility and availability vary by patient and plan type.
By Kiara DeWitt BSN RN CPN | Published: June 1, 2026
Most people searching for Ozempic, Wegovy, and Zepbound cost information hit the same wall. They see a number well above $1,000 per month and assume that’s their only option.
The reality is more complicated, and more hopeful. How much Ozempic, Wegovy, or Zepbound costs without insurance in 2026 depends on which medication you’re looking at, which program you access, what dose you need, and whether you qualify for manufacturer cash-pay pricing. Some of these pathways can bring the monthly cost down dramatically.
This guide breaks down current 2026 pricing for all three medications, compares savings programs, explains what insurance does and doesn’t cover, and covers the compounded GLP-1 alternatives that many patients end up choosing for cost reasons.
Here’s where things stand right now in 2026, before discounts or savings programs:
| Medication | Active Ingredient | FDA-Approved Use | Typical List Price (No Insurance) | Best Available Cash-Pay Price |
| Ozempic | Semaglutide | Type 2 diabetes | ~$1,000/month | ~$199/month (TrumpRx, eligible patients) |
| Wegovy | Semaglutide | Weight loss | ~$1,350/month | $149–$399/month (NovoCare/TrumpRx cash programs) |
| Zepbound | Tirzepatide | Weight loss | ~$1,000–$1,100/month | $299–$449/month (LillyDirect vials) |
| Compounded semaglutide | Semaglutide | Weight loss (off-label) | N/A | From $249/month (supervised programs) |
| Compounded tirzepatide | Tirzepatide | Weight loss (off-label) | N/A | From $425/month (supervised programs) |
Current retail pricing and manufacturer programs continue to evolve in 2026. Prices listed reflect publicly available data as of publication and may change without notice.
These three drugs get lumped together constantly, but they aren’t interchangeable. Understanding the differences helps you know why pricing, insurance coverage, and access vary so much across them.
Ozempic is FDA-approved for type 2 diabetes management. Its active ingredient is semaglutide, the same molecule found in Wegovy. The difference is the approved indication and the dose range.
Ozempic goes up to 2 mg weekly. Insurance is more likely to cover it, but only for patients with a type 2 diabetes diagnosis. Patients who use it for weight loss are doing so off-label, which most commercial insurance plans won’t cover. That’s why so many people end up paying full price.
Wegovy is FDA-approved specifically for chronic weight management. It goes up to 2.4 mg weekly, a higher ceiling than Ozempic. Same molecule, different dose ceiling, different indication. Novo Nordisk also launched the first oral GLP-1 pill for weight loss, Wegovy in tablet form, in January 2026 at significantly lower cash-pay pricing.
Because of the weight loss indication, coverage rules are different. Prior authorization is common, and many commercial plans exclude it entirely.
Zepbound is Eli Lilly’s weight loss brand. Its active ingredient, tirzepatide, works differently from semaglutide. Tirzepatide activates both GLP-1 and GIP receptors, a dual mechanism that clinical trials have linked to greater average weight loss compared to semaglutide-only medications. SURMOUNT-1 trial data published in the New England Journal of Medicine showed average weight loss of 16–23% over 72 weeks, depending on dose.
LillyDirect, Eli Lilly’s direct cash-pay program, has become one of the most-discussed self-pay options in 2026 because of its reduced vial pricing structure.
Ozempic’s list price sits at roughly $1,000 for a monthly supply. That’s the number you’ll likely see at a standard retail pharmacy if you’re paying out of pocket with no assistance.
Brand-name Ozempic pens come in several dose strengths. Unlike some compounded programs that adjust pricing by dose, brand-name Ozempic pricing stays relatively flat across the titration schedule.
| Dose | Approximate Monthly Price (No Insurance) |
| 0.25 mg (starting) | ~$1,000/month |
| 0.5 mg | ~$1,000/month |
| 1 mg | ~$1,000/month |
| 2 mg | ~$1,000/month |
Ozempic doesn’t have a dedicated manufacturer weight-loss cash-pay program the way Wegovy does. Novo Nordisk’s savings offerings for Ozempic are primarily tied to commercial insurance coverage, which means patients without insurance coverage for diabetes get few manufacturer-direct options.
A few options exist for reducing Ozempic costs:
Yes, but access depends on your diagnosis. Because Ozempic is FDA-approved for type 2 diabetes, most telehealth providers require documentation of a diabetes diagnosis to prescribe it. Patients seeking it for weight loss only may be redirected toward Wegovy or compounded semaglutide options.
Wegovy carries one of the highest list prices among GLP-1 medications, sitting around $1,350 for a 28-day supply without insurance or manufacturer discounts. That adds up to roughly $16,200 per year at full price.
Wegovy’s titration schedule goes up to 2.4 mg weekly. Like Ozempic, retail pricing stays mostly flat across dose levels, though this can vary by pharmacy.
| Dose | Approximate Monthly Price (No Insurance) |
| 0.25 mg (starting) | ~$1,350/month |
| 0.5 mg | ~$1,350/month |
| 1 mg | ~$1,350/month |
| 1.7 mg | ~$1,350/month |
| 2.4 mg (maintenance) | ~$1,350/month |
Wegovy pill (oral form, launched January 2026) is priced lower through NovoCare, starting at $149/month for the starting dose and going up to $299/month for higher doses depending on the program.
NovoCare is Novo Nordisk’s direct cash-pay pharmacy program. For eligible patients paying cash for the injectable Wegovy pen, NovoCare pricing starts at $199/month. This is one of the most significant self-pay price drops in the GLP-1 market in 2026.
The NovoCare oral Wegovy pill pricing ranges from $149 to $299/month. Eligibility requirements apply, and the program excludes Medicare and Medicaid patients.
At retail price, Wegovy lists higher than Ozempic even though they share the same active ingredient. Part of this is because Wegovy was developed and marketed specifically for the weight management space, carrying the associated R&D and marketing costs. Through NovoCare and TrumpRx cash programs, however, Wegovy can now often be accessed at lower monthly costs than standard retail Ozempic, which lacks an equivalent manufacturer cash-pay program.
Zepbound’s retail list price falls in the $1,000 to $1,100 range per month for the pre-filled pen version without insurance. Through LillyDirect’s self-pay program, patients paying cash can access Zepbound vials at significantly lower prices.
| Dose | Brand Pen (No Insurance) | LillyDirect Vials (Cash-Pay) |
| 2.5 mg (starting) | ~$1,000–$1,100/month | $299/month |
| 5 mg | ~$1,000–$1,100/month | $299/month |
| 7.5 mg | ~$1,000–$1,100/month | $399/month |
| 10 mg | ~$1,000–$1,100/month | $449/month |
| 12.5 mg | ~$1,000–$1,100/month | $449/month |
| 15 mg (maximum) | ~$1,000–$1,100/month | $449/month |
LillyDirect is Eli Lilly’s direct-to-patient cash-pay platform. As of December 2025, Lilly reduced vial pricing to $299 to $449 per month (down from $349 to $499), depending on dose. Patients order single-dose vials directly through LillyDirect with a valid prescription. This program is cash-pay only and does not apply to pre-filled pens purchased at retail pharmacies.
Eli Lilly also launched a multi-dose KwikPen device for Zepbound in February 2026. This pen contains four doses and is available through LillyDirect.
For patients with qualifying commercial insurance, a Zepbound savings card may reduce monthly costs. Patients on Medicare or Medicaid do not qualify. The card applies at retail pharmacies, not through LillyDirect.
A few reasons drive this switch. Tirzepatide’s dual GLP-1 plus GIP action tends to produce greater average weight loss than semaglutide in head-to-head data. Through LillyDirect’s cash-pay vial program, Zepbound can also be accessed at a lower monthly price than the standard retail cost of Wegovy. Patients who plateaued on semaglutide sometimes find tirzepatide provides renewed progress.
Here’s a side-by-side look at where each medication lands across key cost categories.
Ozempic and Zepbound both list around $1,000/month at retail, making Wegovy the most expensive at approximately $1,350/month before any discounts.
Through cash-pay programs available in 2026, Wegovy pills through NovoCare or TrumpRx can reach $149/month for starting doses, making it the most accessible at the lowest end. LillyDirect Zepbound vials sit at $299–$449/month. Ozempic lacks a comparable direct cash-pay program.
| Medication | Retail List Price | Best Cash-Pay Program Price |
| Ozempic | ~$1,000/month | ~$199/month (TrumpRx, eligible patients) |
| Wegovy injection | ~$1,350/month | $199/month (NovoCare/TrumpRx) |
| Wegovy pill | ~$1,350/month | $149–$299/month (NovoCare/TrumpRx) |
| Zepbound (LillyDirect vials) | ~$1,000–$1,100/month | $299–$449/month |
For patients accessing brand-name options, the Wegovy pill through the NovoCare or TrumpRx program at $149/month for starting doses represents the current lowest point among brand-name GLP-1 medications. For patients who don’t qualify for those programs, compounded semaglutide or tirzepatide from supervised programs generally offers the lowest all-in monthly cost.
Tirzepatide (Zepbound/compounded tirzepatide) consistently shows higher average weight loss in clinical trials compared to semaglutide. If the clinical data holds across individual patients and cost is comparable through cash-pay or compounding programs, tirzepatide tends to deliver more weight loss per dollar spent. That said, individual response varies, and the “right” medication is the one that works for your body and fits your budget and health profile.
Understanding why GLP-1 drugs are expensive helps put the numbers in context. Several factors stack up at once.
Patent protection is the biggest driver. Eli Lilly and Novo Nordisk both hold active patents on their GLP-1 formulations. No generic equivalents exist for the brand-name products, so manufacturers set prices without competition from lower-cost alternatives.
High demand against limited supply pushed prices up significantly between 2022 and 2024. Both companies have invested billions in expanding manufacturing capacity, and supply has improved in 2026, but demand remains high.
Insurance coverage gaps shift full costs to patients. Because most commercial plans don’t cover GLP-1s for weight loss, a large percentage of patients pay cash. Without the negotiating power of insurance, they face retail list pricing.
R&D costs from clinical trials, FDA approval processes, and drug development are priced into the medication over its patent lifecycle.
Generic tirzepatide and semaglutide versions don’t exist yet for the brand-name products. Compounded versions from licensed pharmacies represent the current market alternative, prepared under a different regulatory pathway.
Reducing your monthly GLP-1 cost comes down to which pathways you’re eligible for. Here’s a clear breakdown.
Savings cards from Novo Nordisk and Eli Lilly can dramatically cut out-of-pocket costs for patients with qualifying commercial insurance. The catch: these cards typically don’t work without insurance, don’t apply to Medicare or Medicaid, and have income and eligibility limits.
GoodRx, RxSaver, and similar tools can reduce prices at certain pharmacies, but savings vary. Some Costco and Walmart locations have offered below-average cash prices on certain GLP-1 medications. It’s worth calling several pharmacies in your area to compare.
Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) allow you to use pre-tax dollars for qualifying medical expenses. If a GLP-1 medication is prescribed for a qualifying medical condition, those pre-tax funds can cover both the medication and associated provider costs. This creates an effective savings of 20–30% depending on your tax bracket. For a full breakdown of how this works, read the InjectCo guide on HSA/FSA eligibility for GLP-1 medications.
NovoCare: Novo Nordisk’s direct pharmacy platform offers Wegovy injection at $199/month and Wegovy pill at $149–$299/month for eligible cash-paying patients. This is separate from the savings card and does not require commercial insurance.
LillyDirect: Eli Lilly’s direct platform offers Zepbound single-dose vials at $299–$449/month for cash-paying patients. A valid prescription is required. Supply can be more consistent through this channel than at retail pharmacies.
TrumpRx: A government-partnered direct pricing platform launched in early 2026 that offers Wegovy pens at ~$199/month and Wegovy pills at ~$149/month for eligible patients. Zepbound patients through TrumpRx are currently redirected to LillyDirect.
Yes, compounded GLP-1 medications are consistently cheaper than brand-name options, particularly for patients who don’t qualify for manufacturer cash-pay programs or insurance coverage.
| Medication | Compounded Monthly Range | Brand-Name Comparison |
| Compounded semaglutide | $249–$400/month | ~$1,350/month (Wegovy retail) |
| Compounded tirzepatide | $300–$600/month | ~$1,000–$1,100/month (Zepbound retail) |
InjectCo’s compounded semaglutide program starts at $249/month. The compounded tirzepatide program starts at $425/month. Both include medical evaluation, prescription, monthly supply, and check-ins, not just the medication itself.
The cost difference is the primary driver. For patients without commercial insurance and who don’t qualify for manufacturer programs, compounded semaglutide can cost $700 to $1,100 less per month than brand-name Wegovy at list price.
Other reasons include faster access (no prior authorization process), consistent supply through licensed compounding pharmacies, and the option for supervised, all-inclusive programs that include dose management and side effect support.
The compounded GLP-1 market changed significantly following the FDA’s determination in late 2024 that semaglutide was no longer in shortage. Several compounding pharmacies faced compliance questions, and the regulatory environment tightened.
Compounded medications are not FDA-approved. They are prepared by state-licensed compounding pharmacies under different oversight than brand-name drugs. The quality and safety of a compounded program depends heavily on which pharmacy your provider uses and whether they follow applicable standards.
Patients should always confirm that their provider sources from a licensed 503B compounding pharmacy. You can learn more about best injection sites for semaglutide and how supervised programs support safe self-administration.
Coverage rules vary significantly based on your diagnosis, plan type, and the medication being prescribed. Here’s how it actually breaks down.
Commercial plans are more likely to cover Ozempic and Wegovy for type 2 diabetes management than for weight loss. For the weight loss indication:
For diabetes patients, copays with commercial insurance can run $25 to $100/month for Ozempic. That same patient may be denied coverage entirely if they seek Wegovy under a weight loss diagnosis.
Standard Medicare Part D does not cover GLP-1 medications for weight loss. This has been the law since Medicare Part D was created in 2003.
However, starting July 1, 2026, Medicare launched the “Medicare GLP-1 Bridge” program. This temporary program covers Wegovy (injection and pill), Zepbound (KwikPen), and Foundayo for eligible Medicare Part D enrollees at a $50 per month copay. The program runs through December 31, 2027, and eligibility requires a BMI of 35 or higher, or 27 or higher with qualifying clinical criteria. Prior authorization is required. This $50 copay does not count toward the annual Medicare Part D out-of-pocket cap.
Medicare may also cover:
Coverage in these cases depends on individual plan formularies and prior authorization approval.
Medicaid coverage for GLP-1 medications varies by state. Coverage is generally limited or unavailable for weight loss indications. Patients on Medicaid do not qualify for manufacturer savings cards.
The core issue is a longstanding federal policy that treats obesity differently from diabetes. When a medication is prescribed for blood sugar management, it falls under a covered category. Prescribed for weight loss, it falls under a category that most plans have historically excluded. This is slowly changing through programs like the Medicare GLP-1 Bridge, but commercial plan policies continue to vary widely.
Yes. Several financing options apply to GLP-1 medications, especially through supervised clinical programs.
CareCredit and Cherry are two medical financing companies that allow you to spread the cost of treatment over several months. InjectCo accepts both for compounded semaglutide and tirzepatide programs, with a 6% fee applied. At $249/month for compounded semaglutide, a 6-month financing option through Cherry can bring the monthly payment down to around $150/month.
If you have an HSA or FSA, pre-tax funds can be applied to GLP-1 prescriptions prescribed for qualifying medical conditions. This reduces your effective out-of-pocket cost by 20–30% depending on your tax bracket. See the full InjectCo HSA/FSA guide for semaglutide and tirzepatide for specifics.
Some clinics structure GLP-1 programs as monthly memberships that bundle medication, check-ins, and supplies at a flat rate. This avoids the surprise of add-on charges for visits, dose changes, or supplies. InjectCo’s compounded programs operate on this model.
Telehealth-based GLP-1 programs often have more flexible pricing than in-person clinic programs. They may offer multi-month supply discounts or financing through medical credit. For InjectCo’s compounded semaglutide program, a 4-month supply option is available at $225/month compared to $249/month on a monthly basis.
If brand-name GLP-1 pricing is out of reach and you don’t qualify for manufacturer cash-pay programs, compounded alternatives are the most practical option for most patients.
Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy. It’s prescribed by licensed providers and prepared by state-licensed compounding pharmacies. Monthly pricing typically ranges from $249 to $400, depending on the program and provider.
At InjectCo, compounded semaglutide starts at $249/month and includes everything: evaluation, prescription, monthly supply, supplies, and check-ins. Read more about the InjectCo compounded semaglutide program.
Compounded tirzepatide contains the same active ingredient as Zepbound. Monthly pricing for supervised programs generally runs $300 to $600. InjectCo’s compounded tirzepatide program starts at $425/month with full program support included. Read more at the InjectCo compounded tirzepatide page.
For a detailed comparison of tirzepatide alternatives, see 7 best tirzepatide alternatives.
Supervised medical weight loss programs at licensed clinics offer a different access point than standard pharmacy purchases. These programs include provider oversight, dose guidance, and monitoring, which matters when managing side effects or adjusting to a new medication.
The launch of Wegovy in oral pill form in January 2026 expanded access for patients who prefer not to self-inject. Oral Wegovy through NovoCare starts at $149/month for qualifying patients. Semaglutide sublingual drops are another needle-free option, available through InjectCo at $425/month and including consultation, prescription, and supply. Learn more at the sublingual semaglutide drops page.
No single medication is right for everyone. Your health history, budget, insurance situation, and how your body responds all factor in.
Choose Ozempic if you have a documented type 2 diabetes diagnosis and commercial insurance coverage for diabetes medications. It’s the most likely to be covered and can bring your monthly cost to $25 with a savings card.
Choose Wegovy if you’re seeking an FDA-approved weight loss option and can access NovoCare or TrumpRx cash-pay programs. The pill form launched in 2026 makes it the most accessible low-cost brand-name GLP-1 for many patients at $149/month.
Choose Zepbound if you want the dual GLP-1 plus GIP mechanism and are willing to order through LillyDirect for vial pricing at $299–$449/month. Patients with a history of stalling on semaglutide often see renewed results with tirzepatide.
Choose compounded semaglutide or tirzepatide if you don’t qualify for manufacturer cash-pay programs, don’t have commercial insurance coverage, and want a lower monthly cost through a supervised program.
Talking through your options with a licensed medical provider is the best starting point. They can review your health history, current medications, and weight loss goals before recommending the right fit.
How much does Ozempic cost per month without insurance? Ozempic’s list price is around $1,000 per month without insurance. Through TrumpRx for eligible patients, pricing can drop to approximately $199/month.
How much does Wegovy cost without insurance? Wegovy’s list price is approximately $1,350/month. Through NovoCare or TrumpRx cash programs, the injectable version is available at $199/month, and the pill version starts at $149/month for eligible patients.
Is Zepbound cheaper than Wegovy? At retail list prices, Zepbound runs around $1,000–$1,100/month compared to Wegovy’s ~$1,350/month. Through LillyDirect vials, Zepbound drops to $299–$449/month. Through NovoCare/TrumpRx, Wegovy injection is available at $199/month and the pill at $149/month, making Wegovy potentially cheaper through those programs for qualifying patients.
Which GLP-1 medication is most affordable? Through 2026 manufacturer programs, Wegovy pill via NovoCare or TrumpRx at $149/month is the lowest price for a brand-name option. For patients who don’t qualify for those programs, compounded semaglutide from a supervised clinic (from $249/month) is typically the most affordable medically supervised route.
Does insurance cover Ozempic for weight loss? Rarely. Most commercial plans cover Ozempic for type 2 diabetes management but not for weight loss. Prior authorization for the diabetes indication can bring copays to $25–$100/month for eligible patients.
Can I use a savings card without insurance? No. Manufacturer savings cards for Ozempic, Wegovy, and Zepbound require qualifying commercial insurance coverage. Patients without insurance are not eligible for these cards.
Does Medicare cover Wegovy or Zepbound? Starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy and Zepbound for eligible Medicare Part D enrollees at a $50/month copay. Eligibility requires meeting BMI criteria and qualifying clinical documentation. The program runs through December 31, 2027. Standard Medicare does not cover these drugs for weight loss outside this program.
Are compounded GLP-1 medications still available? Yes, though the regulatory environment tightened after the FDA’s semaglutide shortage determination in 2024. Compounded semaglutide and tirzepatide are still available through licensed 503B compounding pharmacies working with supervised clinical programs. Availability and pricing vary by provider.
Can I use HSA or FSA funds for Ozempic? Yes, in most cases, if the medication is prescribed for a qualifying medical condition. HSA and FSA rules require a valid prescription and an eligible diagnosis. Always confirm with your plan administrator. Read the InjectCo guide on FSA and HSA eligibility for medical weight loss for a full breakdown.
What is the cheapest way to get semaglutide? For brand-name semaglutide, NovoCare or TrumpRx cash programs bring Wegovy to $149–$199/month for eligible patients. For patients who don’t qualify, compounded semaglutide from a supervised program is generally the lowest-cost option, often starting at $249/month with full clinical support included.
What is the cheapest way to get tirzepatide? LillyDirect vials start at $299/month for Zepbound without insurance. Compounded tirzepatide programs at licensed clinics run $300–$600/month, with InjectCo’s supervised program starting at $425/month including evaluation, prescription, and monthly monitoring.
Is Zepbound more effective than Wegovy? Clinical trial data shows tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) at comparable treatment durations. The SURMOUNT-1 trial reported 16–23% average body weight reduction with tirzepatide. Individual results vary based on dose, lifestyle factors, and how your body responds to each medication.
Why are GLP-1 medications so expensive? Active patent protection means no generic competition for brand-name drugs. High demand, the cost of large-scale clinical trials, and insurance coverage gaps all push prices up. Without insurance negotiating prices down, patients often face full retail costs.
Can I finance weight loss injections? Yes. Medical credit options through CareCredit and Cherry allow you to spread the cost of supervised GLP-1 programs over several months. InjectCo accepts both with a 6% financing fee.
Which GLP-1 medication gives the best value? This depends on what you qualify for. For patients who can access NovoCare or TrumpRx, Wegovy pill at $149/month is a strong value. For patients without access to those programs, compounded tirzepatide at $300–$425/month through a supervised program gives a lower monthly cost than brand-name Zepbound while delivering the same active ingredient with clinical oversight.
The $1,000-plus monthly price tag that shows up at a standard pharmacy is rarely the full picture. In 2026, manufacturer cash-pay programs, direct pricing platforms, and supervised compounded programs have created multiple lower-cost access points that most patients don’t know about until they ask.
Ozempic, Wegovy, and Zepbound are brand-name medications. They carry the cost of patent protection, large-scale manufacturing, and commercial distribution. What InjectCo offers through our compounded semaglutide and tirzepatide programs contains the same active ingredients, prepared by licensed 503B compounding pharmacies, at a fraction of the retail price and with full clinical supervision built in.
If you’ve been pricing these medications and deciding whether you can afford to start, the comparison matters. Brand-name Wegovy at retail is $1,350/month. Compounded semaglutide through a supervised InjectCo program starts at $249/month and includes your evaluation, prescription, monthly supply, check-ins, and supplies. Compounded tirzepatide starts at $425/month with the same full-program structure.
You can learn more about InjectCo’s compounded semaglutide program or compounded tirzepatide program and book a free virtual consultation to see which option fits your goals, budget, and health history.
Medical Disclaimer: This content is for educational and informational purposes only. It does not constitute medical or financial advice. Drug pricing is subject to change. GLP-1 medication eligibility, safety, and appropriate use require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved. Always consult a licensed medical professional before starting any prescription weight loss treatment.
